×
Vaxxinity Share Holder Equity 2020-2023 | VAXX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Vaxxinity share holder equity from 2020 to 2023. Share holder equity can be defined as the sum of preferred and common equity items
View More
Vaxxinity Share Holder Equity 2020-2023 | VAXX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Vaxxinity share holder equity from 2020 to 2023. Share holder equity can be defined as the sum of preferred and common equity items
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$214.8B
Amgen (AMGN)
$160.4B
Gilead Sciences (GILD)
$135.3B
Vertex Pharmaceuticals (VRTX)
$119B
Bristol Myers Squibb (BMY)
$97.8B
CSL (CSLLY)
$78.3B
GSK (GSK)
$74.7B
Regeneron Pharmaceuticals (REGN)
$59.4B
Alnylam Pharmaceuticals (ALNY)
$42.3B
Argenex SE (ARGX)
$35B
BioNTech SE (BNTX)
$26.7B
Royalty Pharma (RPRX)
$19.9B
Insmed (INSM)
$19.8B
Biogen (BIIB)
$18.9B
Illumina (ILMN)
$15.5B
Genmab (GNMSF)
$14.5B
Genmab (GMAB)
$14.1B
Incyte (INCY)
$13.3B
Moderna (MRNA)
$12.5B
Exelixis (EXEL)
$12.2B
BioMarin Pharmaceutical (BMRN)
$11.2B
Ascendis Pharma (ASND)
$10.8B
QIAGEN (QGEN)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Exact Sciences (EXAS)
$9.8B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$7.9B
Legend Biotech (LEGN)
$7.7B